The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects

Diabetes and Metabolism

Volumn 25, Issue 3, 1999, Pages 199-211

  Lamarche, B ^a   Lemieux, I ^b   Despres J P ^b  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

Coronary heart disease; Insulin resistance; LDL; Small and dense LDL; Triglycerides

Indexed keywords

ACIPIMOX; APOLIPOPROTEIN B; BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CORONARY RISK; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFICACY; EXERCISE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK MANAGEMENT;

ANTILIPEMIC AGENTS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; PHENOTYPE; REFERENCE VALUES; RISK FACTORS;

EID: 0032881725     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-9.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. N Engl J Med, 1998, 339, 1349-57.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333, 1301-7.
4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279, 1615-1622.
5. Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, et al. Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol, 1995, 76, 98C-106C.
6. Sniderman AD, Genest JJ. The measurement of apolipoprotein B should replace the conventional lipid profile in screening for cardiovascular risk. Can J Cardiol, 1992, 8, 133-140.
7. Genest JJ, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormality in men with premature coronary heart disease. J Am Coll Cardiol, 1992, 19, 792-802.
8. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary heart disease. Am J Cardiol, 1991, 67, 1185-9.
9. Ginsburg GS, Safran C, Pasternak RC. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with desirable total cholesterol levels. Am J Cardiol, 1991, 68: 187-92.
10. Superko HR. Beyond LDL cholesterol reduction. Circulation, 1996, 94, 2351-54.
11. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol, 1994, 5, 395-403.
12. Krauss RM, Blanche PJ. Detection and quantitation of LDL subfractions. Curr Opin Lipidol, 1992, 3, 377-383.
13. Lindgren FT, Jensen LC, Wills RD, Freeman NK. Flotation rate, molecular weight and hydrated densities of the low density lipoproteins. Lipids, 1969, 4, 337-44.
14. Adams GH, Schumaker VN. Equilibrium banding of low-density lipoproteins. 3. Studies on normal individuals and the effects of diet and heparin-induced lipase. Biochim Biophys Acta, 1970, 210, 462-72.
15. Adams GH, Schumaker VN. Polydispersity of human low-density lipoproteins. Ann N Y Acad Sci, 1969, 164, 130-46.
16. Fisher WR. Heterogeneity of plasma low density lipoproteins: manifestations of the physiologic phenomenon in man. Metabolism, 1983, 32, 283-91.
17. Hammond MG, Fisher WR. The characterization of a discrete series of low density lipoproteins in the disease, hyper-pre-beta-lipoproteinemia. Implications relating to the structure of plasma lipoproteins. J Biol Chem, 1971, 246, 5454-65.
18. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res, 1982, 23, 97-104.
19. Albers JJ, Chen CH, Aladjem F. Human serum lipoproteins. Evidence for three classes of lipoproteins in Sf 0 -2. Biochemistry, 1972, 11, 57-63.
20. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arterioscler Thromb Vasc Biol, 1987, 7, 483-90.
21. Austin MA, Jarvik GP, Hokanson JE, Edwards K. Complex segregation analysis of LDL peak particle diameter. Genet Epidemiol, 1993, 10, 599-604.
22. Tchernof A, Lamarche B, Nadeau A, Moorjani S, Labrie F, Lupien PJ, et al. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care, 1996, 19, 629-37.
23. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation, 1990, 82, 495-506.
24. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988, 260, 1917-21.
25. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol, 1996, 7, 167-, 71.
26. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb Vasc Biol, 1992, 12, 187-95.
27. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infaction. Atherosclerosis, 1991, 90, 67-80.
28. Coresh J, Kwiterovich PO. Small, dense low-density lipoprotein particles and coronary heart disease risk - A clear association with uncertain implications. JAMA, 1996, 276, 914-5.
29. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis, 1994, 106, 241-53.
30. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res, 1993, 34, 1687-97.
31. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA, 1996, 276, 882-8.
32. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA, 1996, 276, 875-81.
33. Lamarche B, Tchernof A, Dagenais GR, Cantin B, Lupien PJ, Després JP. Small, dense LDL particles and the risk of ischemic heart disease. Prospective results from the Québec Cardiovascular Study. Circulation, 1997, 95, 69-75.
34. Austin MA, Krauss RM. LDL density and atherosclerosis. JAMA, 1995, 273, 115-.
35. Sniderman AD, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO, Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human low density (beta) lipoproteins]. Proc Natl Acad Sci USA, 1980, 77, 604-8.
36. Sniderman AD, Silberberg J. Is it time to measure apolipoprotein B? Arterioscler Thromb Vasc Biol, 1990, 10, 665-7.
37. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO. Association of hyperapobetalipoprpteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med, 1982, 97, 833-9.
38. Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem, 1996, 42, 489-91.
39. de Graaf J, Hak Lemmers HL, Hectors MP, Demacker PNM, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb Vasc Biol, 1991, 11, 298-306.
40. de Graaf J, Hendriks JC, Demacker PNM, Stalenhoef AF. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb Vasc Biol, 1993, 13, 712-9.
41. Tribble DL, Holl IG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six LDL subfractions of differing density and particle size. Atherosclerosis. 1992, 93, 189-99.
42. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res, 1991, 32, 1741-53.
43. Galeano NF, Milne R, Marcel YL, Walsh MT, Levy E, Ngu'yen TD, et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem, 1994, 269, 511-9.
44. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res, 1998, 39, 1263-73.
45. La Belle M, Krauss RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res, 1990, 31, 1577-88.
46. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis, 1992, 95, 69-76.
47. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest, 1993, 92, 141-6.
48. Austin MA, Mykkänen L, Kuusisto J, Edwards K, Nelson C, Haffner SM, et al. Prospective study of small LDLs as risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation, 1995, 92, 1770-8.
49. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non- insulin-dependent diabetes. Arterioscler Thromb Vasc Biol. 1992, 12, 1496-502.
50. Tan KCB, Cooper MB, Ling KLE, Griffin BA, Freeman DJ, Packard CJ, et al. Fasting and postprandial determinants for the occurence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridemia: the involvement of insulin precursor species and insulin resistance. Atherosclerosis, 1995, 113, 273-87.
51. McNamara JR, Jenner JL, Li Z, Wilson PWF, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb Vasc Biol, 1992, 12, 1284-90.
52. Lahdenperä S, Sane T, Vuorinen-Markkola H, Knudsen P, Taskinen MR. LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. Atherosclerosis, 1995, 113, 227-36.
53. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arterioscler Thromb Vasc Biol, 1990, 10, 497-511.
54. Lemieux S, Prud'homme D, Moorjani S, Tremblay A, Bouchard C, Lupien PJ, et al. Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men? Atherosclerosis, 1995, 118, 155-64.
55. Després JP, Lemieux S, Lamarche B, Prud'homme D, Moorjani S, Brun LD, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes, 1995, 19 Suppl 1, S76-86.
56. Tall AR. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J Intern Med, 1995, 237, 5-12.
57. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res, 1993, 34, 1255-74.
58. Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effects on patients'risk. Obesity Research, 1998, 6 (suppl 1): 8S-17S.
59. Després JP. Lipoprotein metabolism in visceral obesity. Int J Obes, 1991, 15 (Suppl 2), 45-52.
60. Després JP, Ferland M, Moorjani S, Nadeau A, Tremblay A, Lupien PJ. Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arterioscler Thromb Vasc Biol, 1989, 9, 485-92.
61. Lemieux I, Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A, et al. The small, dense LDL phenotype of visceral obesity as correlate of post-prandial lipemia in men. Int J Obes Relat Metab Disord, 1998, 22 (suppl 3), Abstract P454.
62. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et at. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med, 1996, 334, 952-7.
63. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation, 1998, 97, 996-1001.
64. Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med, 1984, 76, 4-12.
65. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA, 1986, 256, 2835-8.
66. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol, 1992, 70, 733-7.
67. Manninen V, Tenkanen L, Koshinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation, 1992, 55, 37-45.
68. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation, 1995, 92, 1779-85.
69. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol, 1997, 17, 1114-20.
70. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol, 1995, 75, 1189-95.
71. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation, 1996, 94, 273-8.
72. Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA, 1998, 279, 1955-61.
73. Grundy SM. Small, dense LDL, atherogenic dyslipidemias, and the metabolic syndrome. Circulation, 1997, 95, 1-4.
74. Dreon DM, Fernstrom HA, Miller B, Krauss RM. Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J, 1994, 8, 121-6.
75. Krauss RM, Dreon DM. Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men. Am J Clin Nutr, 1995, 62, 478S-87S.
76. Dreon DM, Fernstrom HA, Miller B, Krauss RM. Apolipoprotein E isoform phenotype and LDL subclass response to a reduced-fat diet. Arterioscler Thromb Vasc Biol, 1995, 15, 105-11.
77. Dreon DM, Fernstrom HA, Campos H, Blanche P, Williams PT, Krauss RM. Change in dietary saturated fat intake is correlated with change in mass of large low-density-lipoprotein particles in men. Am J Clin Nutr, 1998, 67, 828-36.
78. Kendall A, Levitsky DA, Strupp BJ, Lissner L. Weight loss on a low-fat diet: consequence of the imprecision of the control of food intake in humans. Am J Clin Nutr, 1991, 53, 1124-9.
79. Markovic TP, Campbell LV, Balasubramanian S, Jenkins AB, Fleury AC, Simons LA, et al. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care, 1998, 21, 695-700.
80. Williams PT, Krauss RM, Vranizan KM, Wood PD. Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation, 1990, 81, 1293-304.
81. Purnell JQ, Brunzell JD. The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. Curr Opin Lipidol, 1997, 8, 17-22.
82. Després JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev, 1993, 6, 137-59.
83. Després JP, Lamarche B. Low-intensity endurance exercise training, plasma lipoproteins and the risk of coronary heart disease. J Intern Med. 1994, 236, 7-22.
84. Williams PT, Krauss RM, Wood PD, Lindgren FT, Giotas C, Vranizan KM. Lipoprotein subfractions of runners and sedentary men. Metabolism, 1986, 35, 45-52.
85. Halle M, Berg A, Konig D, Keul J, Baumstark MW. Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men. Metabolism, 1997, 46, 186-91.
86. Williams PT, Krauss RM, Vranizan KM, Albers JJ, Terry RB, Wood PD. Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men. Arterioscler Thromb Vasc Biol, 1989, 9, 623-32.
87. Houmard JA, Bruno NJ, Bruner RK, McCammon MR, Israel RG, Barakat HA. Effects of exercise training on the chemical composition of plasma LDL. Arterioscler Thromb Vasc Biol, 1994, 14, 325-30.
88. Baumstark MW, Frey I, Berg A. Acute and delayed effects of prolonged exercise on serum lipoproteins. II. Concentration and composition of low-density lipoprotein subfractions and very low-density lipoproteins. Eur J Appl Physiol, 1993, 66, 526-30.
89. Lamon-Fava S, McNamara JR, Farber HW, Hill NS, Schaefer EJ. Acute changes in lipid, lipoprotein, apolipoprotein, and low-density lipoprotein particle size after an endurance triathlon. Metabolism, 1989, 38, 921-5.
90. Parks EJ, German JB, Davis PA, Frankel EN, Kappagoda CT, Rutledge JC, et al. Reduced oxidative susceptibility of LDL from patients participating in an intensive atherosclerosis treatment program. Am J Clin Nutr, 1998, 68, 778-85.
91. Beard CM, Barnard RJ, Robbins DC, Ordovas JM, Schaefer EJ. Effects of diet and exercise on qualitative and quantitative measures of LDL and its susceptibility to oxidation. Arterioscler Thromb Vasc Biol, 1996, 16, 201-7.
92. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med, 1988, 319, 24-33.
93. Zhao SP, Hollaar L, van't Hooft FM, Smelt AHM, Leuven JAG, van der Laarse A. Effect of simvastatin on the apparent size of LDL particles in patients with type IIb hyperlipoproteinemia. Clinica Chimica Acta, 1991, 205, 109-18.
94. Pietro DA, Alexander S, Mantell G, Staggers JE, Cook TJ. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). Am J Cardiol, 1989, 63, 682-6.
95. Tilly-Kiesi M. The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism, 1991, 40, 623-8.
96. Yuan J, Tsai MY, Hewgland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis, 1991, 87, 147-57.
97. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb Vasc Biol, 1993, 13, 170-89.
98. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb Vasc Biol, 1994, 14, 1569-75.
99. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis, 1993, 102, 107-19.
100. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998, 98, 2088-93.
101. Lahdenpera S, Tilly KM, Vuorinen MH, Kuusi T, Taskinen MR. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care, 1993; 16, 584-92.
102. Yuan JN, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis, 1994;110, 1-11.
103. Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis, 1992; 95, 35-42.
104. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis, 1993;100, 91-102.
105. Chapman MJ, Bruckert E. The atherogenic role of triglycerides and small, dense low density lipoproteins: Impact of ciprofibrate therapy. Atherosclerosis, 1996;124, S21-S28
106. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Mikami Y, et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis, 1994;106, 191-201.
107. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest, 1984; 74, 470-82.
108. Kesaniemi YA, Grundy SM. Influence of probucol on cholesterol and lipoprotein metabolism in man. J Lipid Res, 1984; 25, 780-90.
109. Miettinen M, Turpeinen O, Karvonen MJ, Elosuo R, Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet, 1972; 2, 835-8.
110. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis, 1989; 9, 462-9.
111. Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol, 1988; 62, 66B-72B.
112. Homma Y, Moriguchi EH, Sakane H, Ozawa H, Nakamura H, Goto Y. Effects of probucol on plasma lipoprotein subfractions and activities of lipoprotein lipase and hepatic triglyceride lipase. Atherosclerosis, 1991; 88, 175-81.
113. Young SG, Witztum JL, Carew TE, Krauss RW, Lindgren FT. Colestipol-induced changes in LDL composition and metabolism. II. Studies in humans. J Lipid Res, 1989; 30, 225-38.
114. Griffin BA, Caslake MJ, Gaw A, Yip B, Packard CJ, Shepherd J. Effects of cholestyramine and acipimox on subfractions of plasma low density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects. Eur J Clin Invest, 1992; 22, 383-90.
115. Fuccella LM, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V, et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther, 1980; 28, 790-5.
116. Franceschini G, Bernini F, Michelagnoli S, Bellosta S, Vaccarino V, Fumagalli R, et al. Lipoprotein changes and increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia. Atherosclerosis, 1990; 81, 41-9.